DLH wins $2m NIH data governance pilot for biomedical research

DLH Holdings (NASDAQ: DLHC) has been awarded a $2 million task order by the National Institutes of Health to design, develop, and pilot a data governance framework for controlled biomedical research data. The 18-month contract represents new work for the Atlanta-based federal technology services firm and covers technical advisory services across NIH's sprawling portfolio of research data platforms.

Under the terms of the award, DLH will act as a technical advisor to harmonise NIH and federal data policies, integrating governance workflows across biomedical data platforms. The pilot will be conducted within the National Heart, Lung, and Blood Institute and at least one other NIH institute or centre. If successful, the framework is positioned by the company as a potential roadmap for NIH-wide adoption.

Scope and technical remit

DLH's remit goes beyond standard data management. The company will incorporate requirements covering security, privacy, data rights, and AI governance, and will collect performance metrics across usability, compliance, interoperability, and stakeholder satisfaction. The inclusion of AI governance requirements is notable: NIH holds some of the most sensitive controlled-access genomic and clinical datasets in the US federal system, and pressure to open those datasets to AI-driven research has been growing even as regulators tighten access controls.

Brooke Pierce, President of DLH's Health business group, said the award "expands our role as a technical and strategic advisor to NIH and brings together DLH's expertise in biomedical research, data governance, and secure digital solutions." Pierce added that the company sees the work as a foundation for pursuing broader enterprise-scale modernisation opportunities if NIH evaluates wider adoption of the framework.

Market and regulatory context

Federal data governance is a contested and growing market. The White House Office of Management and Budget has pushed agencies toward consistent data-sharing and interoperability standards under directives including the Federal Data Strategy, while the National Institutes of Health has its own controlled-access framework for genomic data managed through the database of Genotypes and Phenotypes (dbGaP). Aligning those layers with newer AI governance requirements, as mandated by the Biden-era Executive Order on AI and subsequent OMB guidance, is a non-trivial technical task that several federal IT integrators are competing to address.

DLH operates in a market that includes larger defence and health IT primes such as Leidos, Booz Allen Hamilton, and ICF, as well as a range of mid-tier federal technology services companies. At $2 million, this task order is modest relative to DLH's reported annual revenue base, but it carries strategic weight as a named proof-of-concept inside one of NIH's largest institutes. A successful pilot could convert into a much larger enterprise-wide modernisation contract, which is why Pierce's forward-looking comment about future opportunities is the more commercially significant signal in this release.

Standards path

Any NIH-wide data governance framework will need to align with NIST's Risk Management Framework, FedRAMP authorisation requirements for cloud-based data platforms, and the agency's existing controlled-access policies under the NIH Genomic Data Sharing Policy. The AI governance component adds another layer, given that OMB Memorandum M-24-10 requires federal agencies to appoint Chief AI Officers and conduct impact assessments for AI used in government decision-making. DLH's ability to navigate that multi-framework landscape will be a key test of the pilot's credibility.

The task order begins immediately; DLH has not disclosed which NIH institute beyond NHLBI will participate in the pilot phase.